Jim Cramer on Royalty Pharma: “It’s a Terrific Company”

Royalty Pharma plc (NASDAQ:RPRX) is one of the stocks Jim Cramer shared his take on. A caller asked for Cramer’s take on the stock, and here’s what he had to say:

Royalty just keeps going higher… I love that whole business where they help fund bio, and they get the returns. It’s a terrific company. I remember when GA brought it public, and I liked it then, I like it now.

Stock market data. Photo by Alesia Kozik on Pexels

Royalty Pharma plc (NASDAQ:RPRX) makes money by buying up royalties for multiple drugs and funding new research in the biotech world. Its current line-up includes a vast number of treatments from cancer to rare diseases. On January 11, the company announced that it had entered into a funding agreement with Teva Pharmaceuticals to accelerate the clinical development of TEV-‘408, an anti-IL-15 antibody targeting several autoimmune diseases. CEO and Chairman of the Board of Royalty Pharma plc (NASDAQ:RPRX), Pablo Legorreta, said:

Vitiligo is a chronic autoimmune skin disease that can have a profound emotional and psychosocial burden, yet current treatment options are insufficient. Our continued collaboration underscores Royalty Pharma’s role as a long-term, trusted partner with a focus on funding innovation in potentially transformative and practice changing therapies.

While we acknowledge the risk and potential of RPRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RPRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.